Evaluating the Causal Effects of Low Density Lipoprotein Cholesterol Levels on Ischemic Stroke: A Mendelian Randomization Study

被引:0
作者
Hou, Xiaowen [1 ]
Zheng, Jiaqi [1 ]
Zhang, Jiajun [1 ]
Tao, Lin [2 ]
Cen, Kaiwen [1 ]
Cui, Ying [1 ]
Wu, Ji [1 ]
机构
[1] Shenyang Med Coll, Sch Publ Hlth, Shenyang 110034, Peoples R China
[2] Shenyang Med Coll, Sch Int Educ, Shenyang 110034, Peoples R China
关键词
Low -density lipoprotein cholesterol; Ischemic stroke; Mendelian randomization; Causality;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Ischemic stroke (IS) is the leading cause of disability and mortality worldwide. Low-density lipoprotein cholesterol (LDL-C) levels hadno potential risk on ischemic stroke. However, higher LDL-C levels were closely related to IS. Based on two antagonistic viewpoints, a Mendelian randomization (MR) study was designed to evaluate the causal effects of LDL-C levels on IS. Methods: Datasets of LDL-C levels and ischemic stroke were acquired from genome-wide association studies (GWAS). Weighted median method was conducted for main analysis, and MR -Egger and inverse -variance weighted (IVW) methods were performed for auxiliary analyses. Heterogeneity and pleiotropic tests were utilized to confirm the reliability of this study. Results: A total of 359 single nucleotide polymorphisms (SNPs) were associated with LDL-C levels (P < 5 x 10(-8)) and 337 SNPs were available in ischemic stroke with eliminating outliers. LDL-C levels were significantly associated with ischemic stroke (OR = 1.104, 95%CI = 1.019 - 1.195, P = 1.52 x 10(-2)). MR -Egger and IVW showed directionally similar estimates (MR -Egger: OR = 1.120, 95%CI = 1.040 - 1.207, P = 3.12 x 10(-3); IVW: OR = 1.120, 95%CI = 1.064 - 1.178, P = 1.17 x 10(-5)). Conclusion: LDL-C levels had causal effects on IS, providing insights into the design of future interventions to reduce the burden of ischemic stroke.
引用
收藏
页码:397 / 403
页数:7
相关论文
共 16 条
  • [1] Meta-analysis and Mendelian randomization: A review
    Bowden, Jack
    Holmes, Michael, V
    [J]. RESEARCH SYNTHESIS METHODS, 2019, 10 (04) : 486 - 496
  • [2] Modifiable and non-modifiable risk factors in ischemic stroke: a meta-analysis
    Cui, Qinyuan
    Naikoo, Niyaz Ahmad
    [J]. AFRICAN HEALTH SCIENCES, 2019, 19 (02) : 2121 - 2129
  • [3] Reduction of low density lipoprotein- cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
    Ference, Brian A.
    Cannon, Christopher P.
    Landmesser, Ulf
    Luescher, Thomas F.
    Catapano, Alberico L.
    Ray, Kausik K.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2540 - 2545
  • [4] Ischemic Stroke
    Feske, Steven K.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2021, 134 (12) : 1457 - 1464
  • [5] Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
    Lee, Jennifer S.
    Chang, Po-Yin
    Zhang, Ying
    Kizer, Jorge R.
    Best, Lyle G.
    Howard, Barbara V.
    [J]. DIABETES CARE, 2017, 40 (04) : 529 - 537
  • [6] Treatments in Ischemic Stroke: Current and Future
    Mosconi, Maria Giulia
    Paciaroni, Maurizio
    [J]. EUROPEAN NEUROLOGY, 2022, 85 (05) : 349 - 366
  • [7] Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke
    Ntaios, George
    Milionis, Haralampos
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (05) : 476 - 482
  • [8] Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
    Packard, Chris
    Chapman, M. John
    Sibartie, Mahendra
    Laufs, Ulrich
    Masana, Luis
    [J]. HEART, 2021, 107 (17) : 1369 - 1375
  • [9] Putaala Jukka, 2020, Continuum (Minneap Minn), V26, P386, DOI 10.1212/CON.0000000000000833
  • [10] Rabinstein Alejandro A, 2017, Continuum (Minneap Minn), V23, P62, DOI 10.1212/CON.0000000000000420